Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Will End Avandia Promotion Worldwide

This article was originally published in The Pink Sheet Daily

Executive Summary

Even in countries where the drug will still be sold, the firm projects "minimal" sales.

You may also be interested in...



GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes

GSK expects Tanzeum will be one of its “core big six” drugs despite the fact that it is the fourth GLP-1 to market. VP-General Medicines Cheryl MacDiarmid discussed GSK’s return to diabetes in an interview.

Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off

TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia

China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use

SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel